TET2 and acute myeloid leukemia: Among CN-AML patients, patients under 65 years of age harboring TET2 mutations had more reduced OS (HR: 1.999, P = 0.001) and EFS(HR: 1.741, P = 0.005) compared with those harboring wild type.